17
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Necessity of Multiple Gastric Biopsies from Different Sites for Detection of Clarithromycin-Resistant Helicobacter pylori Strains

, , , , , & show all
Pages 942-946 | Published online: 08 Jul 2009

  • Unge P. Assessment and significance of Helicobacter pylori infection. Aliment Pharmacol Ther 1997:11 Suppl 2:33-9.
  • Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Helicobacter priori infection is the major risk factor for atrophie gastritis. Am J Gastroenterol 1996:91:959-62.
  • Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992:116:705-8.
  • Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, et al. Helicobacter pylori infection is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol 2000;35:255-9.
  • Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, et al. K-ras mutation in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Im J Cancer 2002:97:562-6.
  • Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter priori. Lancet 1993:342:575-7.
  • NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994:272:65-9.
  • Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997:41:8-13.
  • Eind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996; 1:138-44.
  • Pilotto A, Franceschi M, Rassu M, Leandro G, Bozzola L, Furlan F, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000:32:667-72.
  • Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shiratori Y, et al. Detection of clarithromycin-resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol 2000:38:210-4.
  • Marais A, Monteiro L, Occhialini A, Pina M, Lamouliatte H, Mégraud F. Direct detection of Helicobacter pylori resistance to macrolides by polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999:44:463-7.
  • Matsuoka M, Yoshida Y, Hayakawa K, Fukuchi S, Sugano K. Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. Gut 1999:45:503-7.
  • Wang G, Taylor DE. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 1998:42:1952-8.
  • Alarcón T, Domingo D, Prieto N, López-Brea M. PCR-using 3'mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J Clin Microhiol 2000:38:923-5.
  • Versalovic .1, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997:40:283-6.
  • Hiyama T, Yokozaki H, Shimamoto F, Haruma K, Yasui W, Kajiyama G, et al. Frequent p53 gene mutations in serrated adenomas of the colorectum. J Pathol 1998:186:131-9.
  • Hiyama T, Haruma K, Kitadai Y, Ito M, Masuda H, Miyamoto M, et al. Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ra.v alteration and microsatellite instability. Im J Oncol 2001:18:1207-12.
  • Yokozaki H, Shitara Y, Fujimoto .1, Hiyama T, Yasui W, Tahara E. Alterations p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. hit J Cancer 1999:83: 192-6.
  • Moazed D, Noller HF. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of the 23S ribosomal RNA. Biochimie 1987:69:879-84.
  • Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouliatte H, Mégraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to rihosomes. Antimicrob Agents Chemother 1997:41:2724-8.
  • van Doom LJ, Glupczynski Y, Kusters JG, Mégraud F, Midolo P, Maggi-Solca N, et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother 2001; 45: 1500-4.
  • Stone GG, Shortridge D, Versalovic J, Beyer J, Flamm RK, Graham DY, et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicohucterpriori. Antimicrob Agents Chemother 1997:41:712-4.
  • Umegaki N, Shimoyama T, Nishiya D, Suto T, Fukuda S, Munakata A. Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter priori isolates from Japan. J Gastroenterol Hepatol 2000:15:906-9.
  • Matsumura M, Hikiba Y, Ogura K, Togo G, Tsukuda I, Ushikawa K, et al. Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol 2001:39:691-5.
  • Kalo M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000:44: 2214-6.
  • Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999:43:2747-52.
  • Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 1998:43:317-21.
  • Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999:13:775-80.
  • Wang G, Rahman MS, Humayun MZ, Taylor DE. Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter priori. Antimicrob Agents Chemother 1999:43:683-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.